GE launches nuclear medicine platform
Other headlines:TomoTherapy enters Middle East
GE launches nuclear medicine platform
A new breed of gamma technology will soon join the GE Healthcare portfolio for nuclear cardiology. The company's newly released Alcyone platform combines cadmium zinc telluride (CZT) detectors, focused pin-hole collimation, 3D reconstruction, and stationary data acquisition to improve workflow, dose management, and overall image quality, according to the company. The technology platform, set to be unveiled March 29 at the American College of Cardiology meeting, will be available on both the Discovery NM 530c and the Discovery NM/CT 570c. Heightened sensitivity and zero equipment motion translate into improved image quality and energy resolution, potentially enabling new clinical applications. Among them are 3D dynamic acquisitions and simultaneous dual-isotope imaging. The new platform will cut scan times from 15 to 20 minutes to three to five minutes, according to GE. A shorter, more comfortable scan promises to improve image quality by reducing the likelihood of artifacts.
TomoTherapy enters Middle East
Saudi Arabia's leading cancer center, King Faisal Specialist Hospital and Research Centre in Riyadh, is the first in the Middle East to offer patients treatment with TomoTherapy's Hi•Art radiation therapy system. A ribbon-cutting ceremony held March 9 inaugurated the image-guided intensity-modulated radiation therapy system.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
